Contact
Please use this form to send email to PR contact of this press release:
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
TO:
Please use this form to send email to PR contact of this press release:
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
TO: